Technical briefing 9 This briefing provides an update on previous briefings up to 1 April 2021 Summary • There are 4 variants of concern and 7 variants under investigation (Table 1). VOC-20DEC-01 (B.1.1.7) remains predominant in the UK. Other variants of concern and variants under investigation remain a very low proportion of the available sequence […]
Category Archives: diagnostic article
Technical briefing 8 This briefing provides an update on previous briefings up to 11 March 2021 Summary • There are 4 variants of concern and 6 variants under investigation (Table 1). Definitions for variants of concern, variants under investigation and signals in monitoring have been updated. VOC-20DEC-01 (B.1.1.7) remains predominant. Other variants of concern and […]
Variant of Concern 2021/03 Technical briefing 7 This briefing provides an update on previous briefings up to 13 February 2021 Summary • There are 4 variants of concern and 5 variants under investigation (Table 1) • A slightly increased risk of hospitalisation has been now been detected for VOC 202012/01 (B.1.1.7), supporting previous findings on […]
Variant of Concern 202012/01Technical briefing 6 This briefing provides an update on previous briefings up to 1 February 2021 Summary There are 4 variants of concern, designated: • VOC 202012/01 (B.1.1.7), first detected in Kent England is predominant in all regions and is circulating in multiple countries• VOC 202102/02 (B.1.1.7 cluster with E484K mutation), first detected in South West […]
Variant of Concern 202012/01Technical briefing 5 This briefing provides an update on the briefing of 14 January 2021 Summary SGTF detections indicate VOC202012/01 continues to predominate across all regions. S gene target failure remains a well correlated proxy measure of VOC 202012/01. An assessment of severity of disease has been conducted by NERVTAG. A limited […]
Variant of Concern 202012/01 Technical briefing 4 This briefing provides an update on the briefing of 8 January 2021 Nomenclature of variants in the UK SARS-CoV-2 variants if considered to have concerning epidemiological, immunological or pathogenic properties are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, […]
Variant of Concern 202012/01Technical briefing 3 Nomenclature of variants in the UK SARS-CoV-2 variants if considered to have concerning epidemiological, immunological or pathogenic properties are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, month, and number. Following risk assessment with the relevant expert committee, they may […]
137 candidate vaccines in clinical evaluation ID Vaccine platform acronym Vaccine platform description Type of candidate vaccine Route of administration Developers Phase Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 Phase 4 1 IV Inactivated virus CoronaVac; SARS-CoV-2 vaccine (inactivated) IM Sinovac Research and Development Co., Ltd Phase 4 NCT04383574 NCT04754698** NCT04456595 NCT04756830 […]
Guangdi Li1 and Erik De Clercq2 1 Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China. 2 Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium. https://doi.org/10.1038/d41573-020-00016-0 Supplementary Table 1 | Summary of antiviral compounds against human coronaviruses Virus-based treatment strategies 2019-nCoV;Influenza RdRp Favipiravir […]
GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) Spike-N501Y mutation Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) spike-N501Y mutation, which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies. SARS-COV-2 (2019nCOV) variant-N501Y mutation of Spike […]
